Ona Therapeutics

September ended and October began with an explosion of new venture capital available for biotech companies, raising expectations for VC fundraising by drug developers through the rest of 2024, especia

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Organon Will Market Lilly’s Emgality, R

Gene therapy is hardly flavor of the month for investors at the moment but that has not stopped SpliceBio from signing off the largest ever series A financing in Spain for a biotech company. SpliceB

Spain's biotech sector has come a long way in the last decade or so, with its strong science capabilities now augmented by significant investment, much of which has come from Ysios, the country's larg